Efficiency of application of sorbed probiotics in complex therapy of pneumonia caused by SARS-CoV-2. Part 1. Heating clinical displays period

Abstract

Aim. To determine the clinical efficacy and safety of the sorbed probiotics Bifidobacterium bifidum 1 (5108 KОЕ) and B. bifidum 1 (5107 KОЕ) in combination with Lactobacillus plantarum 8P-А3 in the complex therapy of pneumonia caused by SARS-CoV-2 in adult patients without severe risk factors.
 Materials and methods. An open, randomized prospective study included 100 patients (45 men, 55 women), aged 18 to 60 years without risk factors for severe COVID-19 with pneumonia confirmed by computed tomography, and an area of lung lesion no more than 75% (moderate forms). SARS-CoV-2 RNA in nasal and oropharyngeal swabs (RT-PCR) was detected in 72% of the participants, in the rest it was highly probable in terms of the aggregate parameters. Diagnostics of COVID-19 and its severity, the appointment of a standard examination and treatment were carried out in accordance with the Temporary Methodological Recommendations of the Ministry of Health of Russia, version 8 of 09.03.2020. This publication presents the results of using B. bifidum 1 (3 capsules twice a day for 10 days) during the peak of clinical manifestations (in a hospital).
 Results. In those who received sorbed B. bifidum 1, by the 10th day of treatment, the frequency of weakness was 32% lower (RR 0.55 [95% CI 0.240.73], OR 0.25 [0.110.59]); hypoosmia/dysgeusia by 22% (RR 0.42 [0.050.65], OR 0.40 [0.170.90]) and cough by 24% (RR 0.39 [0.070.60], OR 0.38 [0.170.84]). B. bifidum 1 reduced the average duration of weakness by 3 days [1.14.9], hypoosmia/dysgeusia by 3.2 days [1.35.1], cough by 1.9 days [0.43,4], dyspnea by 1.8 days [0.72.7], diarrhea by 1.7 days [0.13.5]; reduced the risk of antibiotic-associated diarrhea by 20% (RR 0.77 [0.240.93], OR 0.18 [0.050.68]). Due to the deterioration of the condition and the increase in the symptoms of respiratory failure, additional treatment was required less often by 24% (p=0.005). After the end of the intervention, the frequency of virologic debridement, levels of CRP, leukocytes, lymphocytes, platelets and the degree of lung damage on computed tomography did not statistically differ in the compared groups. No side effects of B. bifidum 1 (5108 KОЕ) have been identified.
 Conclusion. The use of sorbed B. bifidum 1 (5108 KОЕ) improved the well-being of patients without risk factors with moderate viral (SARS-CoV-2) pneumonia and reduced the duration of diarrheal syndrome in a short time. The safety profile of their use was high. More research is needed to clarify the anti-inflammatory effects of the sorbed probiotic.

Retracted: Gut microbiota and COVID‐19: A systematic review

“… 119 In addition, three studies noted the effectiveness of probiotics in treating diarrhea among COVID‐19 patients. 29 , 34 , 146 Similar studies have reported consistent results with our study that probiotics can treat gut dysbiosis and thus mitigate the GI symptoms arising from it. 155 , 156 One RCT conducted in China reported that the use of Bifidobacterium, Lactobacillus, Enterococcus , and Bacillus tablets was associated with a better immune function and reduced secondary bacterial or fungal infection.…”

“…The majority of the studies found the probiotics beneficial for COVID‐19 patients’ recovery. 29 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 45 , 70 , 76 , 77 One study evaluated the positive efficacy of FMT (Fecal microbial transplantation) for COVID‐induced GI upset. 33 Zhang et al reported that probiotics reduced the length of COVID‐19 illness and hospitalization.…”

Efficiency of application of sorbed probiotics in the complex therapy of pneumonia caused by SARS-CoV-2. Quality of life in the short term COVID-19

“…У пациентов с синдромом раздраженной кишки пробиотики приводили к снижению степени депрессии и лимбической активности в ответ на отрицательные эмоциональные стимулы [30]. В первой части исследования, опубликованной ранее [20], помимо вероятного противовоспалительного эффекта, обсуждалась возможность косвенного влияния сорбированных пробиотиков на личностное восприятие симптомов. Получавшие ПС значительно реже отмечали одышку при физической нагрузке в своих дневниках (ОШ 0,09; 95% ДИ 0,02-0,04; р<0,001) по сравнению с получавшими стандартную терапию, хотя степень повреждения легких была умеренной.…”

“…В данном исследовании не проводили спирометрию после госпитализации, что можно отметить в качестве ограничения исследования. У 6 и 20% пациентов в параллельных группах отмечали увеличение степени поражения легких до КТ3-4 [20]. Средний уровень С-реактивного белка в момент выписки из стационара оставался умеренно повышенным: 21,2±15,0 и 27,3±20,0 мг/л (р>0,05) в сравниваемых группах соответственно.…”

“…Настоящее исследование посвящено оценке эффективности и безопасности российских препаратов сорбированных пробиотиков в комплексной терапии среднетяжелой формы пневмонии, вызванной SARS-CoV-2. Отчет о результатах 1-й части исследования был опубликован ранее [20], в настоящей публикации представлена 2-я часть исследования, которая посвящена анализу течения периода реконвалесценции и КЖ, связанного со здоровьем, через 1 мес после госпитализации.…”